TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05711394: A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Sponsor: AbbVie · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$3,305,760

Rescue Site Savings

+$2,203,840

Unlock Full NCT05711394 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05711394 Rescue Dossier →